PRAX on XNAS, Health Care, Praxis Precision Medicines, Inc., job postings
Measures activity, not value. Not investment advice.
Shares rose 83% in a year, but short interest is 15% of shares, up 7.3% on the prior report.
GoodInstitutional holders rose 9.8% to 335 from the quarter before
Watch59% of its 144 open job postings are sales and business development
Written by AI from the data on this page, 21 Nov 2026. Not investment advice.
Profile and fundamentals
From its SEC filings, 12 months to 30 Sep 2026
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.
expected around 5 Jan 2027 (an estimate: a year ago it reported on 6 Jan 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: net loss $94.2M.
31 Dec 2021RevenueNet incomeNet losstallest bar $94.2M30 Sep 2026
See the numbers
Quarter to
Revenue
Net income
30 Sep 2026
–
-$94.2M
30 Jun 2026
–
-$83.7M
31 Mar 2026
–
-$92.6M
31 Dec 2025
$0
-$88.9M
30 Sep 2025
$0
-$73.9M
30 Jun 2025
$0
-$71.1M
31 Mar 2025
$0
-$69.3M
31 Dec 2024
$7.5M
-$58.7M
30 Sep 2024
$302K
-$51.9M
30 Jun 2024
$357K
-$32.7M
31 Mar 2024
$431K
-$39.6M
31 Dec 2023
$515K
-$26.9M
30 Sep 2023
$468K
-$24.6M
30 Jun 2023
$781K
-$34.3M
31 Mar 2023
$683K
-$37.5M
31 Dec 2022
$0
-$41.2M
30 Sep 2022
$0
-$43.9M
30 Jun 2022
$0
-$60.2M
31 Mar 2022
$0
-$68.7M
31 Dec 2021
–
-$58.6M
Fundamentals, 12 months to 30 Sep 2026
Measure
Latest
Year before
Peer median
RevenueiSales over the last 12 months reported.
–
$7.5M
Revenue growthiRevenue of the last 12 months compared with the 12 months before.
–
+11%
Net incomeiProfit after all costs and taxes over the last 12 months reported. Negative is a loss.
-$359.4M
-$273.0M
EPS (diluted)iEarnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split).
-$12.81
-$12.96
Gross marginiWhat is left of each dollar of sales after the direct cost of making the product or service.
–
–
73.2%
Operating marginiOperating income as a share of sales: profit from the business before interest and taxes.
–
–
-25.0%
Net marginiNet income as a share of sales: what the owners keep of each dollar sold.
–
–
-18.2%
Return on equityiNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money.
-44.8%
-58.8%
Free cash flowiCash from operations minus capital spending over the last 12 months: cash the business produced.
–
-$228.9M
CashiCash, cash equivalents and short-term investments on the latest balance sheet.
$1.3B
$389.2M
DebtiShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted.
$0
$0
Net debtiDebt minus cash. Negative means the company holds more cash than it owes (net cash).
-$1.3B (net cash)
-$389.2M
Debt to equityiDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative.
0.0
0.0
Book value per shareiShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding.
$45.06
P/EiPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss.
loss
19.3
P/SiPrice to sales: market cap divided by revenue of the last 12 months.
–
5.0
EV/SalesiEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months.
–
5.0
P/BiPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative.
6.7
2.0
Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.
Peers nearest by market cap, its own industry first
Insider Buy/Sell iShares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.
–
No data for this company
Institutional holders iThe number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.
+9.8%
335 13F filers vs 305
Institutional ownership iShares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.
over 100%
34.6M shares held by 13F filers (30 Sep 2026) of 28.0M outstanding (4 Nov 2026); above 100%: the share count is probably stale
Short interest iShares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.
15%
4.2M shares sold short (30 Oct 2026) of 28.0M outstanding (4 Nov 2026)
Days to cover iShort interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.
8.7
4.2M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it
Short interest change iHow the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.
+7.3%
3.9M shares sold short in the report before, 4.2M on 30 Oct 2026
Short sale volume iShare of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.
67%
67% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 63%
Open jobs iJob postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.
144
Tracked since 20 Nov 2026
Open jobs change iHow the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.
–
Tracking started 20 Nov 2026; the change shows after 30 days.
Employees iTotal staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.
–
No headcount in its annual reports in our data.
Visa hiring (foreign workers) iApplications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.
–
No data for this company
Revenue growth iSales in the latest reported quarter compared with the same quarter a year earlier.
–
No data for this company
Capital spending iMoney spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.
–
No data for this company
Federal contracts iMoney the US government committed to the company in contracts and grants over the last 12 months.
–
No data for this company
Lobbying iWhat the company reported spending on federal lobbying over the last four quarters.
$280K
4 quarters, $
Layoff notices iWorkers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).
–
No data for this company
News (7d) iArticles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.
30
30 articles in the last 7 days; its usual week has 8.5 (the median of the 26 weeks before).
News vs usual iArticles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.
3.5×
30 articles in the last 7 days; its usual week has 8.5.
Unusual now sharp changes in the last 90 days, compared with its own past
Lobbying spend $160K, 4.0× a year earlier
New institutional positions 70, 2.7× a year earlier
New lobbying issue
Price $300.43 on 20 Nov 2026, +83% over 12 months (12-month range $164.09 to $386.33)
Sharp change
8-K and other filings
Lobbying filing
Insider net buying (open market). Insiders sold a net $3.6M in the last 12 months (the 12 months before: -$40.7M).H-1B/E-3 applications certified. H-1B/E-3 applications certified: 4 published in the last 12 months (none in the 12 months before).Revenue per quarter. Revenue $0 in the latest quarter, -100% on a year earlier.Capital spending per quarter. Capital spending $245K in the latest quarter, +338% on a year earlier.Institutional holders (13F filers). 335 13F filers reported holding it in the latest 13F quarter, +131% on a year earlier.Lobbying spend. Lobbying spend: $280K published in the last 12 months, +87% on the 12 months before.
Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: federal obligations, workers in warn layoff notices.
Quarter ended 31 Mar 2022: $0; public on 12 May 2023
Quarter ended 30 Jun 2022: $0; public on 10 Aug 2023
Quarter ended 30 Sep 2022: $0; public on 8 Nov 2023
Quarter ended 31 Dec 2022: $0; public on 6 Mar 2024
Quarter ended 31 Mar 2023: $683K; public on 12 May 2023
Quarter ended 30 Jun 2023: $781K; public on 10 Aug 2023
Quarter ended 30 Sep 2023: $468K; public on 8 Nov 2023
Quarter ended 31 Dec 2023: $515K; public on 6 Mar 2024
Quarter ended 31 Mar 2024: $431K, -37% on a year earlier; public on 14 May 2024
Quarter ended 30 Jun 2024: $357K, -54% on a year earlier; public on 14 Aug 2024
Quarter ended 30 Sep 2024: $302K, -35% on a year earlier; public on 7 Nov 2024
Quarter ended 31 Dec 2024: $7.5M, +1349% on a year earlier; public on 1 Mar 2025
Quarter ended 31 Mar 2025: $0, -100% on a year earlier; public on 3 May 2025
Quarter ended 30 Jun 2025: $0, -100% on a year earlier; public on 5 Aug 2025
Quarter ended 30 Sep 2025: $0, -100% on a year earlier; public on 6 Nov 2025
Quarter ended 31 Dec 2025: $0, -100% on a year earlier; public on 20 Feb 2026
Capital spending per quarter
Quarter ended 31 Mar 2022: $289K, +7125% on a year earlier; public on 10 May 2022
Quarter ended 30 Jun 2022: $110K, +69% on a year earlier; public on 9 Aug 2022
Quarter ended 30 Sep 2022: $45K, -90% on a year earlier; public on 10 Nov 2022
Quarter ended 31 Mar 2023: $0, -100% on a year earlier; public on 12 May 2023
Quarter ended 30 Jun 2023: $0, -100% on a year earlier; public on 10 Aug 2023
Quarter ended 30 Sep 2023: $0, -100% on a year earlier; public on 8 Nov 2023
Quarter ended 31 Dec 2023: $50K; public on 6 Mar 2024
Quarter ended 30 Sep 2024: $0; public on 6 Nov 2025
Quarter ended 31 Dec 2024: $0, -100% on a year earlier; public on 1 Mar 2025
Quarter ended 31 Mar 2025: $0; public on 8 May 2026
Quarter ended 30 Jun 2025: $56K; public on 5 Aug 2025
Quarter ended 30 Sep 2025: $0; public on 6 Nov 2025
Quarter ended 31 Dec 2025: $0; public on 20 Feb 2026
Quarter ended 31 Mar 2026: $62K; public on 8 May 2026
Quarter ended 30 Jun 2026: $245K, +338% on a year earlier; public on 7 Aug 2026
Institutional holders (13F filers)
31 Dec 2021 report: 91; public on 14 Feb 2022
31 Mar 2022 report: 101; public on 16 May 2022
30 Jun 2022 report: 89; public on 15 Aug 2022
30 Sep 2022 report: 100; public on 14 Nov 2022
31 Dec 2022 report: 100; public on 14 Feb 2023
31 Mar 2023 report: 84; public on 15 May 2023
30 Jun 2023 report: 75; public on 14 Aug 2023
30 Sep 2023 report: 70; public on 14 Nov 2023
31 Dec 2023 report: 57; public on 14 Feb 2024
31 Mar 2024 report: 108; public on 15 May 2024
30 Jun 2024 report: 112; public on 14 Aug 2024
30 Sep 2024 report: 131; public on 14 Nov 2024
31 Dec 2024 report: 161; public on 14 Feb 2025
31 Mar 2025 report: 147; public on 15 May 2025
30 Jun 2025 report: 138; public on 14 Aug 2025
30 Sep 2025 report: 145; public on 14 Nov 2025
31 Dec 2025 report: 238; public on 17 Feb 2026
31 Mar 2026 report: 280; public on 15 May 2026
30 Jun 2026 report: 305; public on 14 Aug 2026
30 Sep 2026 report: 335; public on 16 Nov 2026
Lobbying spend
Quarter from 1 Apr 2023: $40K published
Quarter from 1 Jul 2023: $40K published
Quarter from 1 Oct 2023: $40K published
Quarter from 1 Jan 2024: $40K published
Quarter from 1 Apr 2024: $30K published
Quarter from 1 Jul 2024: $30K published
Quarter from 1 Oct 2024: $30K published
Quarter from 1 Jan 2025: $30K published
Quarter from 1 Apr 2025: $40K published
Quarter from 1 Jul 2025: $40K published
Quarter from 1 Oct 2025: $40K published
Quarter from 1 Jan 2026: $40K published
Quarter from 1 Apr 2026: $40K published
Quarter from 1 Jul 2026: $40K published
Quarter from 1 Oct 2026: $160K published
What is unusual now
Made public in the last 90 days: it reported $160K of lobbying spend for the quarter ended 30 Sep 2026, 4.0× the same quarter last year; it also saw 70 13F filers open a new position in the quarter ended 30 Sep 2026, 2.7× the same quarter last year. 3 sharp changes in all. Two or more unrelated kinds of activity agreed on 17 Nov 2026.
Lobbying spend jump: reported $160K of lobbying spend for the quarter ended 30 Sep 2026, 4.0× the same quarter last year Public on 21 Oct 2026.
Many funds opening a new position: saw 70 13F filers open a new position in the quarter ended 30 Sep 2026, 2.7× the same quarter last year Public on 16 Nov 2026.
144 open postings; careers site tracked since 20 Nov 2026. Most in Sales & business development 59%, Marketing & communications 11%, Program & project management 11%, Legal, policy & compliance 7%.
Reported lobbying spend: $160K in Q3 2026, $40K in Q2 2026. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.
Date
Change
Lobbying firm
Issue
Source
11 Jul 2026
New
Ballard Partnersfor Praxis Precision Medicines, Inc.
Engagement and strategy for the FDA and HHS related to product pipeline.Health issues
The KPM Group DC LLCfor Praxis Precision Medicines
Rare disease drug development Orphan Drug Act Orphan Drug Tax Credit Priority Review Voucher Expedited approval pathways Patient-focused drug development Neurology Drug ProgramHealth issues, Pharmacy
Two or more unrelated kinds of records unusual within 30 days
17 Nov 2026confirmed
Confirmed across sources Institutional holdings and Lobbying
Praxis Precision Medicines(PRAX): reported $160K of lobbying spend for the quarter ended 30 Sep 2026, 4.0× the same quarter last year, while it saw 70 13F filers open a new position in the quarter ended 30 Sep 2026, 2.7× the same quarter last year. Two unrelated kinds of activity within 27 days.
Lobbying: Lobbying on a new issue, became public on 21 Oct 2026
Lobbying: Lobbying spend jump, became public on 21 Oct 2026
Institutional holdings: Many funds opening a new position, became public on 16 Nov 2026
The quarter ended 30 Sep 2026 against the 8 quarters before it.
this quarterearliernormal: $40KSee the evidence (3 changes)
Lobbying: Lobbying on a new issue became public on 21 Oct 2026
Praxis Precision Medicines lobbying on a new issue.
New
['HCR']
Rule
only points whose every posting (and value revision) is at or before as_of
Field
issue_codes
Metric
lobbying.filings_count
Point id
9641691
Lobbying: Lobbying spend jump became public on 21 Oct 2026
Praxis Precision Medicines reported $160K of lobbying spend for the quarter ended 30 Sep 2026, 4.0× the same quarter last year.
This period
$160K (the quarter ended 30 Sep 2026)
Normal quarter (median of 8 earlier)
$40K
Typical spread (median absolute deviation)
$0
How far from its usual level
+6.0
Same quarter last year
$40K
History used
1,279 days
the quarter ended 30 Sep 20268 earlier quartersnormal: $40K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least $100K.
Institutional holdings: Many funds opening a new position became public on 16 Nov 2026
Praxis Precision Medicines saw 70 13F filers open a new position in the quarter ended 30 Sep 2026, 2.7× the same quarter last year.
This period
70 (the quarter ended 30 Sep 2026)
Normal quarter (median of 8 earlier)
32.5
Typical spread (median absolute deviation)
7
How far from its usual level
+3.6
Same quarter last year
26
History used
2,099 days
the quarter ended 30 Sep 20268 earlier quartersnormal: 32.5
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
14 Jun 2022confirmed
Confirmed across sources Insiders and Short interest and volume
Praxis Precision Medicines(PRAX): had 3 insiders buy $113K of its shares on the open market within 30 days (3 filings), while it had 4.1M shares sold short in the 31 May 2022 report, 3.2× the same report last year. Two unrelated kinds of activity within 63 days.
Short interest and volume: Short interest spike, became public on 11 May 2022
Short interest and volume: Short interest spike, became public on 25 May 2022
Insiders: Clustered insider buying, became public on 14 Jun 2022
Short interest and volume: Short interest spike, became public on 10 Jun 2022
Short interest and volume: Short interest spike, became public on 28 Jun 2022
Short interest and volume: Short interest spike, became public on 13 Jul 2022
The 31 May 2022 report against the 24 reports before it.
this reportearliernormal: 1.5MSee the evidence (6 changes)
Short interest and volume: Short interest spike became public on 11 May 2022
Praxis Precision Medicines had 3.6M shares sold short in the 29 Apr 2022 report, 1.9× the same report last year.
This period
3.6M (the 29 Apr 2022 report)
Normal report (median of 24 earlier)
1.5M
Typical spread (median absolute deviation)
233K
How far from its usual level
+5.9
Same report last year
1.8M
History used
546 days
the 29 Apr 2022 report24 earlier reportsnormal: 1.5M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 25 May 2022
Praxis Precision Medicines had 3.8M shares sold short in the 13 May 2022 report, 2.4× the same report last year.
This period
3.8M (the 13 May 2022 report)
Normal report (median of 24 earlier)
1.5M
Typical spread (median absolute deviation)
233K
How far from its usual level
+6.6
Same report last year
1.6M
History used
560 days
the 13 May 2022 report24 earlier reportsnormal: 1.5M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.
Short interest and volume: Short interest spike became public on 10 Jun 2022
Praxis Precision Medicines had 4.1M shares sold short in the 31 May 2022 report, 3.2× the same report last year.
This period
4.1M (the 31 May 2022 report)
Normal report (median of 24 earlier)
1.5M
Typical spread (median absolute deviation)
233K
How far from its usual level
+7.5
Same report last year
1.3M
History used
578 days
the 31 May 2022 report24 earlier reportsnormal: 1.5M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 28 Jun 2022
Praxis Precision Medicines had 2.9M shares sold short in the 15 Jun 2022 report, 2.0× the same report last year.
This period
2.9M (the 15 Jun 2022 report)
Normal report (median of 24 earlier)
1.5M
Typical spread (median absolute deviation)
249K
How far from its usual level
+3.7
Same report last year
1.5M
History used
593 days
the 15 Jun 2022 report24 earlier reportsnormal: 1.5M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 13 Jul 2022
Praxis Precision Medicines had 3.6M shares sold short in the 30 Jun 2022 report, 2.9× the same report last year.
This period
3.6M (the 30 Jun 2022 report)
Normal report (median of 24 earlier)
1.6M
Typical spread (median absolute deviation)
309K
How far from its usual level
+4.4
Same report last year
1.3M
History used
608 days
the 30 Jun 2022 report24 earlier reportsnormal: 1.6M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
Timeline
Changes and notable records, by the date each became public
17 Nov 2026several at once
reported $160K of lobbying spend for the quarter ended 30 Sep 2026, 4.0× the same quarter last year, while it saw 70 13F filers open a new position in the quarter ended 30 Sep 2026, 2.7× the same quarter last year. Two unrelated kinds of activity within 27 days.
See the evidence (3 changes)
Lobbying: Lobbying on a new issue became public on 21 Oct 2026
Praxis Precision Medicines lobbying on a new issue.
New
['HCR']
Rule
only points whose every posting (and value revision) is at or before as_of
Field
issue_codes
Metric
lobbying.filings_count
Point id
9641691
Lobbying: Lobbying spend jump became public on 21 Oct 2026
Praxis Precision Medicines reported $160K of lobbying spend for the quarter ended 30 Sep 2026, 4.0× the same quarter last year.
This period
$160K (the quarter ended 30 Sep 2026)
Normal quarter (median of 8 earlier)
$40K
Typical spread (median absolute deviation)
$0
How far from its usual level
+6.0
Same quarter last year
$40K
History used
1,279 days
the quarter ended 30 Sep 20268 earlier quartersnormal: $40K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least $100K.
Institutional holdings: Many funds opening a new position became public on 16 Nov 2026
Praxis Precision Medicines saw 70 13F filers open a new position in the quarter ended 30 Sep 2026, 2.7× the same quarter last year.
This period
70 (the quarter ended 30 Sep 2026)
Normal quarter (median of 8 earlier)
32.5
Typical spread (median absolute deviation)
7
How far from its usual level
+3.6
Same quarter last year
26
History used
2,099 days
the quarter ended 30 Sep 20268 earlier quartersnormal: 32.5
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
16 Nov 2026Institutional holdings change
saw 70 13F filers open a new position in the quarter ended 30 Sep 2026, 2.7× the same quarter last year.
Same quarter last year: 26; its normal quarter is 32.5.
See the evidence
This period
70 (the quarter ended 30 Sep 2026)
Normal quarter (median of 8 earlier)
32.5
Typical spread (median absolute deviation)
7
How far from its usual level
+3.6
Same quarter last year
26
History used
2,099 days
the quarter ended 30 Sep 20268 earlier quartersnormal: 32.5
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
reported $160K of lobbying spend for the quarter ended 30 Sep 2026, 4.0× the same quarter last year.
Same quarter last year: $40K; its normal quarter is $40K.
See the evidence
This period
$160K (the quarter ended 30 Sep 2026)
Normal quarter (median of 8 earlier)
$40K
Typical spread (median absolute deviation)
$0
How far from its usual level
+6.0
Same quarter last year
$40K
History used
1,279 days
the quarter ended 30 Sep 20268 earlier quartersnormal: $40K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least $100K.
saw 68 13F filers open a new position in the quarter ended 31 Mar 2026, 2.1× the same quarter last year.
Same quarter last year: 33; its normal quarter is 32.5.
See the evidence
This period
68 (the quarter ended 31 Mar 2026)
Normal quarter (median of 8 earlier)
32.5
Typical spread (median absolute deviation)
5.5
How far from its usual level
+4.4
Same quarter last year
33
History used
1,916 days
the quarter ended 31 Mar 20268 earlier quartersnormal: 32.5
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
saw 93 13F filers open a new position in the quarter ended 31 Dec 2025, 2.9× the same quarter last year.
Same quarter last year: 32; its normal quarter is 30.
See the evidence
This period
93 (the quarter ended 31 Dec 2025)
Normal quarter (median of 8 earlier)
30
Typical spread (median absolute deviation)
4.5
How far from its usual level
+9.4
Same quarter last year
32
History used
1,826 days
the quarter ended 31 Dec 20258 earlier quartersnormal: 30
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
had 3.8M shares sold short in the 31 Dec 2025 report, 2.0× the same report last year.
Same report last year: 1.9M; its normal report is 2.1M.
See the evidence
This period
3.8M (the 31 Dec 2025 report)
Normal report (median of 24 earlier)
2.1M
Typical spread (median absolute deviation)
292K
How far from its usual level
+3.9
Same report last year
1.9M
History used
1,888 days
the 31 Dec 2025 report24 earlier reportsnormal: 2.1M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 3.7M shares sold short in the 15 Dec 2025 report, 2.4× the same report last year.
Same report last year: 1.5M; its normal report is 2.1M.
See the evidence
This period
3.7M (the 15 Dec 2025 report)
Normal report (median of 24 earlier)
2.1M
Typical spread (median absolute deviation)
279K
How far from its usual level
+3.9
Same report last year
1.5M
History used
1,872 days
the 15 Dec 2025 report24 earlier reportsnormal: 2.1M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 3.6M shares sold short in the 28 Nov 2025 report, 2.4× the same report last year.
Same report last year: 1.5M; its normal report is 2.0M.
See the evidence
This period
3.6M (the 28 Nov 2025 report)
Normal report (median of 24 earlier)
2.0M
Typical spread (median absolute deviation)
256K
How far from its usual level
+4.1
Same report last year
1.5M
History used
1,855 days
the 28 Nov 2025 report24 earlier reportsnormal: 2.0M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 3.6M shares sold short in the 14 Nov 2025 report, 2.4× the same report last year.
Same report last year: 1.5M; its normal report is 2.0M.
See the evidence
This period
3.6M (the 14 Nov 2025 report)
Normal report (median of 24 earlier)
2.0M
Typical spread (median absolute deviation)
206K
How far from its usual level
+5.4
Same report last year
1.5M
History used
1,841 days
the 14 Nov 2025 report24 earlier reportsnormal: 2.0M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 3.1M shares sold short in the 31 Oct 2025 report, 1.8× the same report last year.
Same report last year: 1.7M; its normal report is 1.9M.
See the evidence
This period
3.1M (the 31 Oct 2025 report)
Normal report (median of 24 earlier)
1.9M
Typical spread (median absolute deviation)
188K
How far from its usual level
+4.1
Same report last year
1.7M
History used
1,827 days
the 31 Oct 2025 report24 earlier reportsnormal: 1.9M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 2.6M shares sold short in the 30 Sep 2025 report, 1.5× the same report last year.
Same report last year: 1.8M; its normal report is 1.9M.
See the evidence
This period
2.6M (the 30 Sep 2025 report)
Normal report (median of 24 earlier)
1.9M
Typical spread (median absolute deviation)
143K
How far from its usual level
+3.6
Same report last year
1.8M
History used
1,796 days
the 30 Sep 2025 report24 earlier reportsnormal: 1.9M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
saw 56 13F filers open a new position in the quarter ended 31 Mar 2024, 5.1× the same quarter last year.
Same quarter last year: 11; its normal quarter is 14.
See the evidence
This period
56 (the quarter ended 31 Mar 2024)
Normal quarter (median of 8 earlier)
14
Typical spread (median absolute deviation)
3.5
How far from its usual level
+8.1
Same quarter last year
11
History used
1,186 days
the quarter ended 31 Mar 20248 earlier quartersnormal: 14
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.
had 3.6M shares sold short in the 30 Jun 2022 report, 2.9× the same report last year.
Same report last year: 1.3M; its normal report is 1.6M.
See the evidence
This period
3.6M (the 30 Jun 2022 report)
Normal report (median of 24 earlier)
1.6M
Typical spread (median absolute deviation)
309K
How far from its usual level
+4.4
Same report last year
1.3M
History used
608 days
the 30 Jun 2022 report24 earlier reportsnormal: 1.6M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 2.9M shares sold short in the 15 Jun 2022 report, 2.0× the same report last year.
Same report last year: 1.5M; its normal report is 1.5M.
See the evidence
This period
2.9M (the 15 Jun 2022 report)
Normal report (median of 24 earlier)
1.5M
Typical spread (median absolute deviation)
249K
How far from its usual level
+3.7
Same report last year
1.5M
History used
593 days
the 15 Jun 2022 report24 earlier reportsnormal: 1.5M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Showing the newest 40 of 76 entries; narrow the window or the kind of data to see older ones.
Not listed: 112 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.
Identifiers and sources
How records are matched to this company, and what each source holds for it